Matthew P Goetz MDProfessor of Oncology and Pharmacology, Mayo Clinic, Rochester, Minnesota
Matthew P. Goetz, M.D. is a consultant in the Division of Medical Oncology, Department of Oncology, at Mayo Clinic. He holds the academic rank of Professor of Oncology and Pharmacology.
Dr. Goetz leads the breast cancer research activities at the Mayo Clinic where he is chair of the Mayo Breast Cancer Research Group, co-leader of the Women’s Cancer Program within the Mayo Clinic Cancer Center, and Co-PI of the Mayo Clinic Breast Cancer Specialized Program of Research Excellence (SPORE) grant.
Dr. Goetz has been extensively involved in both translational research as well as in the conduct of early and late phase clinical trials. A notable area of Dr. Goetz's focus has been related to the pharmacogenetics of tamoxifen. Emanating from this work and in collaboration with the Developmental Therapeutics Program of the National Cancer Institute (NCI), Dr. Goetz has led a team of investigators in the development of a novel formulation of endoxifen for the treatment of estrogen receptor positive breast cancer.
DisclosuresDr. Goetz reports the following disclosures:
Advisory board: Myriad, Biotheranostics, Lilly, Biovica, Eisai
Funding: Lilly, Pfizer
Recent Contributions to PracticeUpdate:
- Z-Endoxifen for Endocrine Refractory Breast Cancer: An Update
- SABCS 2017: Subgroup Analyses and Patient Selection for CDK4/6 Inhibitor Therapy
- Estimating Outcomes in Triple Negative Breast Cancer From SABCS 2017
- Updates on the Neoadjuvant Treatment of Breast Cancer
- New Insights From SABCS 2016 on Adjuvant Therapy for HR+ Breast Cancer